HD

J04 Benchmarking enroll-HD to a phase III placebo cohort from generation HD1 to inform clinical trial planning
Hannah Furby, Athanasios Siadimas, Peter McColgan, Lauren Boak, Letizia Polito, Eileen Neacy, Jeffrey D Long, Cristina Sampaio

Journal of Neurology, Neurosurgery & Psychiatry Sep 2022, 93 (Suppl 1) A94-A95; DOI: 10.1136/jnnp-2022-ehdn.254
B01 Juvenile HD fused brain organoids of dorsal and ventral origin to understand early neurodevelopmental aspects of neurodegenerative diseases
Karolina Świtońska-Kurkowska, Jakub Kubiś, Joanna M Delimata, Luiza Handschuh, Maciej Figiel

Journal of Neurology, Neurosurgery & Psychiatry Sep 2022, 93 (Suppl 1) A14-A15; DOI: 10.1136/jnnp-2022-ehdn.41
D16 Cerebrospinal fluid biomarkers for assessing Huntington disease onset and severity
Nicholas S Caron, Arsalan S Haqqani, Akshdeep Sandhu, Amirah E Aly, Hailey Findlay Black, Jeffrey N Bone, Jodi L McBride, Abedelnasser Abulrob, Danica Stanimirovic, Blair R Leavitt, Michael R Hayden

Journal of Neurology, Neurosurgery & Psychiatry Sep 2022, 93 (Suppl 1) A25-A26; DOI: 10.1136/jnnp-2022-ehdn.72
A09 Ran-translation products are selectively taken up by a microglia cell line and induce an inflammatory response via the NLRP3 inflammasome pathway
Raul Nicolás Jamin, Cira Dansokho, Michael T Heneka, Patrick Weydt

Journal of Neurology, Neurosurgery & Psychiatry Sep 2022, 93 (Suppl 1) A3-A4; DOI: 10.1136/jnnp-2022-ehdn.9
D01 Two independent validations of a mutant huntingtin protein (MHTT) assay to support the clinical development of mHTT-targeting therapies in HD
David Hawellek, Stephanie Vauleon, Katharina Schutz, Benoit Massonnet, Nanda Gruben, Marianne Manchester, Lauren Boak, Scott Schobel

Journal of Neurology, Neurosurgery & Psychiatry Sep 2021, 92 (Suppl 1) A13; DOI: 10.1136/jnnp-2021-EHDN.32
F14 Collaborating with the community to conduct clinical trials in huntington’s disease: lessons from the tominersen phase iii generation HD1 study
Victoria Liddy, David West, Mai-lise Nguyen, Lauren Boak, Scott Schobel, Nolwen Olivier, Keir Hodge, HD-COPE, Jenny Townhill

Journal of Neurology, Neurosurgery & Psychiatry Sep 2021, 92 (Suppl 1) A24-A25; DOI: 10.1136/jnnp-2021-EHDN.57
G01 Molecular testing for huntington disease and the risk of disclosure of unsolicited pre-symptomatic status: a recurring theme
Elaine Cristina Miglorini, Karina Carvalho Donis, Raphael Castilhos, Maria Luiza Saraiva-Pereira, Laura Bannach Jardim

Journal of Neurology, Neurosurgery & Psychiatry Sep 2021, 92 (Suppl 1) A41; DOI: 10.1136/jnnp-2021-EHDN.98
H01 Disease burden in patients with huntington’s disease from a nationwide swedish registry compared with the general population (2002–2019)
Hannah Furby, Suzanne Moore, Anna-Lena Nordstroem, Richard Houghton, Sophie Graham, Dimitra Lambrelli, Per Svenningsson, Åsa Petersén

Journal of Neurology, Neurosurgery & Psychiatry Sep 2021, 92 (Suppl 1) A42-A43; DOI: 10.1136/jnnp-2021-EHDN.101
H03 Experiences of outpatients with huntington’s disease with case management; a qualitative study
Cindy Kruijthof, Jonieke Bredewold, Loes van Dusseldorp

Journal of Neurology, Neurosurgery & Psychiatry Sep 2021, 92 (Suppl 1) A44; DOI: 10.1136/jnnp-2021-EHDN.103
I15 Inhibition of S1P degradation is beneficial in the transgenic R6/2 mouse model of huntington disease
Alba Di Pardo, Salvatore Castaldo, Enrico Amico, Luca Capocci, Giuseppe Pepe, Vittorio Maglione

Journal of Neurology, Neurosurgery & Psychiatry Sep 2018, 89 (Suppl 1) A93-A94; DOI: 10.1136/jnnp-2018-EHDN.251

Main menu

HD

Pages

Log in using your username and password

Main menu

Log in using your username and password

You are here

HD

Pages